KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBT (2016 - 2025)

Idexx Laboratories has reported EBT over the past 17 years, most recently at $307.0 million for Q4 2025.

  • Quarterly results put EBT at $307.0 million for Q4 2025, up 19.73% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 19.31% YoY), and the annual figure for FY2025 was $1.3 billion, up 19.31%.
  • EBT for Q4 2025 was $307.0 million at Idexx Laboratories, down from $344.8 million in the prior quarter.
  • Over the last five years, EBT for IDXX hit a ceiling of $362.4 million in Q2 2025 and a floor of $171.1 million in Q2 2022.
  • Median EBT over the past 5 years was $257.7 million (2024), compared with a mean of $262.9 million.
  • Biggest five-year swings in EBT: soared 75.54% in 2021 and later tumbled 32.04% in 2022.
  • Idexx Laboratories' EBT stood at $191.9 million in 2021, then grew by 11.12% to $213.2 million in 2022, then grew by 12.41% to $239.7 million in 2023, then rose by 6.98% to $256.4 million in 2024, then rose by 19.73% to $307.0 million in 2025.
  • The last three reported values for EBT were $307.0 million (Q4 2025), $344.8 million (Q3 2025), and $362.4 million (Q2 2025) per Business Quant data.